FDA 483 - Lonza AG - December 15, 2017

An FDA inspection of Lonza AG in Visp, Switzerland, a drug substance manufacturer, revealed one observation. The firm's master production instructions were found to be deficient, specifically lacking defined time and temperature limits for critical processing steps of a starting material. This indicates a potential issue with process control and consistency in manufacturing.